Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 3/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339102 | 0.70 | MAOB (0.33) | — | |
| SCHEMBL21698511 | 0.69 | MAOB (0.32) | — | |
| SCHEMBL21291599 | 0.61 | MC4R (0.37) | LTA4HLMNA | |
| Diphenylmethane SCHEMBL27576617 | 0.61 | CALM1 (0.80) | CALM1LTA4HPLA2G10PLA2G2ALMNA | |
| SCHEMBL972712 | 0.61 | CALM1 (0.92) | CALM1LTA4HPLA2G10PLA2G2ALMNA | |
| SCHEMBL8094422 | 0.61 | CALM1 (0.92) | CALM1LTA4HPLA2G10PLA2G2ALMNA | |
| SCHEMBL25231491 | 0.60 | — | — | |
| SCHEMBL8771463 | 0.60 | CYP3A4 (0.78) | CALM1LTA4HPLA2G10PLA2G2ASLC22A2 | |
| SCHEMBL202238 | 0.60 | CYP3A4 (0.78) | CALM1LTA4HPLA2G10PLA2G2ASLC22A2 | |
| 4,4'-Methylenedianiline SCHEMBL28946261 | 0.60 | CYP3A4 (0.78) | CALM1LTA4HPLA2G10PLA2G2ASLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974779-B2 | Piperidine derivatives as human papilloma virus inhibitors | VAXART, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | VAXART, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | AVIRAGEN THERAPEUTICS INC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9452991-B2 | Piperidine derivatives as human papilloma virus inhibitors | AVIRAGEN THERAPEUTICS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2024350-B1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA | 2012-08-30 | — | — | US | disclosed |
| EP-2024350-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | Anaconda Pharma (FR) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007135106-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | ANACONDA PHARMA (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079968-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | CALM1 2800/4885LTA4H 2694/4885PLA2G10 2589/4885 |
| US-20180021318-A9 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | POLI, VHL, EBNA1BP2 | CALM1 2800/4885LTA4H 2694/4885PLA2G10 2589/4885 |
| US-20120220633-A1 | PIPERIDINE DERIVATIVES AS HUMAN PAPILLOMA VIRUS INHIBITORS | IDH3A, CBR3, CBR1 | CALM1 2237/4885LTA4H 429/4885PLA2G10 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.